Charles River Laboratories CRL Venture Capital And Equity Method Investments, Gain (Loss) And Impairments, Net
Venture Capital And Equity Method Investments, Gain (Loss) And Impairments, Net at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept crl:VentureCapitalAndEquityMethodInvestmentsGainLossAndImpairmentsNet.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net?
- Charles River Laboratories (CRL) reported venture capital and equity method investments, gain (loss) and impairments, net of -$1.14M in Q1 2026.
- How has Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net changed year-over-year?
- Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net increased by 89.0% year-over-year, from -$10.37M to -$1.14M.
- What does venture capital and equity method investments, gain (loss) and impairments, net mean?
- The net profit or loss generated from the company's minority stakes in other businesses.
- How do you interpret venture capital and equity method investments, gain (loss) and impairments, net?
- Positive values indicate successful investment performance, while negative values reflect losses or the need to write down the value of these investments.
- How does venture capital and equity method investments, gain (loss) and impairments, net compare across companies?
- Common for companies with active corporate venture arms or strategic partnerships.